However, when analyzing the relationship between these features and the percentage of GOLPH3 positive cancer cells (“A” score in IRS scale) in the prostate and metastatic lymph node samples, a significant correlation was found with the efficacy of the RP - the efficacy of RP was higher in patients in whom the percentage of GOLPH3 positive cancer cells in prostate was lower (75% vs. 36.7% for 51-80% GOLPH3 positive cells and >80% GOLPH3 positive cells respectively; p=0.001). Here, GOLPH3 is linked to cancer.